# US 12,215,338 B2 · Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,215,338 B2 - Document ID: US12215338B2 - Status: Granted - Kind: B2 - Application number: 17/053,733 - Filed: 2019-05-08 - Published: 2021-12-16 - Granted: 2025-02-04 - Earliest claimed: 2018-05-08 - Assignees: Neuracle Science Co., Ltd.; Neuracle Genetics Inc. - Applicants: Neuracle Science Co., Ltd.; Neuracle Genetics - Inventors: Jong-Mook Kim; Dong Sik Kim; Juwon Shim; Soon-gu Kwon - Web page: https://patentgrep.com/patent/US12215338B2 ## CPC - A61P 25/02: for peripheral neuropathies - C12N 15/86: Viral vectors - A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered} - A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous} - C07K 16/24: against cytokines, lymphokines or interferons - A01K 2207/30: Animals modified by surgical methods - A01K 2227/105: Murine - A01K 2267/0356: Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy - A61K 2039/505: {comprising antibodies} - A61K 2039/53: {DNA (RNA) vaccination} - C07K 2317/622: Single chain antibody (scFv) - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C12N 2750/14141: Use of virus, viral particle or viral elements as a vector - C12N 2750/14143: viral genome or elements thereof as genetic vector - C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS ## Abstract The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv. ## Claims ### Claim 1 An adeno-associated virus (AAV) vector comprising a nucleic acid that encodes an antibody, or an antigen-binding portion thereof, which specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, and wherein: (i) the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16; (ii) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 212; (iii) the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213; (iv) the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 222; (v) the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 225; and (vi) the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 224. ### Claim 2 (depends on 1) The AAV vector of claim 1, further comprising an intron, a signal peptide, one or more adeno-associated virus inverted terminal repeats (ITRs), or any combination thereof. ### Claim 3 (depends on 1) The AAV vector of claim 1, wherein the anti-FAM19A5 antibody comprises a Fab, a Fab′, a F (ab′)2, a Fv, a single chain Fv (scFv), or a combination thereof. ### Claim 4 (depends on 3) The AAV vector of claim 3, wherein the anti-FAM19A5 antibody is a scFv. ### Claim 5 (depends on 1) The AAV vector of claim 1, wherein the nucleic acid is codon optimized. ### Claim 6 An adeno-associated virus (AAV) vector comprising a nucleic acid that encodes an antibody, or an antigen-binding portion thereof, which specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), wherein the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 204, or SEQ ID NO: 301. ### Claim 7 An adeno-associated virus (AAV) vector comprising a nucleic acid that encodes an antibody, or an antigen-binding portion thereof, which specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), wherein the scFv comprises the amino acid sequence set forth in SEQ ID NO: 201 or SEQ ID NO: 256. ### Claim 8 (depends on 1) The AAV vector of claim 1, wherein the anti-FAM19A5 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 236 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 245. ### Claim 9 (depends on 1) The AAV vector of claim 1, wherein the anti-FAM19A5 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence which is at least about 80% identical to the amino acid sequence set forth in SEQ ID NO: 236; and/or wherein the light chain variable region comprises an amino acid sequence which is at least about 80% identical to the amino acid sequence set forth in SEQ ID NO: 245. ### Claim 10 (depends on 1) The AAV vector of claim 1, wherein: (i) the anti-FAM19A5 antibody, or antigen-binding portion thereof, is capable of inhibiting the binding of a reference antibody, or antigen-binding portion thereof, to a human FAM19A5 protein by at least about 10%, as measured by a binding inhibition assay; (ii) the anti-FAM19A5 antibody, or antigen-binding portion thereof, is capable of reducing a concentration of FAM19A5 protein in a culture medium comprising an astrocyte cell line by at least about 10%, as measured by ELISA; or (iii) both (i) and (ii). ### Claim 11 (depends on 1) A composition comprising the AAV vector of claim 1 and a carrier. ### Claim 12 (depends on 1) An isolated host cell comprising the AAV vector of claim 1. ### Claim 13 (depends on 6) The AAV vector of claim 6, wherein the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 301. ### Claim 14 (depends on 13) A composition comprising the AAV vector of claim 13 and a carrier. ### Claim 15 (depends on 7) A composition comprising the AAV vector of claim 7 and a carrier. ### Claim 16 (depends on 7) An isolated host cell comprising the AAV vector of claim 7. ### Claim 17 (depends on 8) A composition comprising the AAV vector of claim 8 and a carrier. ### Claim 18 (depends on 8) An isolated host cell comprising the AAV vector of claim 8. ### Claim 19 (depends on 9) A composition comprising the AAV vector of claim 9 and a carrier. ### Claim 20 (depends on 9) An isolated host cell comprising the AAV vector of claim 9.